Top news of the week from Specialty Pharmacy Times.
Pharmacy benefit manager study indicates that moving patients with hemophilia from standard half-life to extended half-life coagulation factor products carries a significant cost increase.
Pharmacy benefit manager reports specialty drugs drive 97% of spending for hereditary angioedema care.
Spending on specialty medications is rapidly approaching half of overall medicine spending from a small volume of prescriptions filled.
New treatments for cystic fibrosis, migraines, and multiple sclerosis expected to help push specialty drug costs on the pharmacy benefit to nearly 50% of total drug spending by 2020.
Study finds improving adherence to disease-modifying multiple sclerosis medications could reduce clinical relapses while saving on medical costs.